Digestive health disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) significantly affect the quality of life for millions globally. With rising prevalence, earlier diagnoses, and more targeted treatments, the global therapeutics market for IBS and IBD is gaining rapid momentum.
According to BCC Research, the global IBS and IBD therapeutics market is projected to grow from $33.3 billion in 2025 to $52.6 billion by 2030, registering a compound annual growth rate (CAGR) of 9.6%, innovative biologics, small-molecule therapies, microbiome-based approaches, and a strong clinical pipeline fuel this expansion.
From traditional pharmaceutical giants to focused biotech, the following companies are at the forefront of this transformation, delivering better outcomes through personalized care, advanced drug development, and global access strategies.
- AbbVie Inc.
Headquarters: Illinois, USA | Founded: 2013
Key Areas: Biologics for Crohn’s disease, ulcerative colitis, IL-23 pathway inhibitors
AbbVie dominates the IBD space with Humira (adalimumab), one of the most successful biologics globally. It has continued this legacy with Skyrizi (risankizumab), an IL-23 inhibitor recently approved for Crohn’s disease. With strategic investments in immunology R&D, AbbVie remains a global leader in chronic inflammatory gastrointestinal diseases.
- Takeda Pharmaceuticals
Headquarters: Tokyo, Japan | Founded: 1781
Key Areas: Gut-selective biologics, IBS-D/IBS-C treatment, immunology
Takeda plays a dual role in both the IBS and IBD markets. It markets Entyvio (vedolizumab), a gut-selective biologic for ulcerative colitis and Crohn’s, and has a strong presence in IBS therapies. Takeda commands over 30% of the IBS therapeutics market, focusing on cost-effective innovation and global distribution.
- Johnson & Johnson (Janssen Biotech)
Headquarters: New Jersey, USA | Founded: 1886
Key Areas: Advanced biologics, long-term IBD management
Johnson & Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies) offers diverse portfolios spanning multiple therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. It is a leading provider of gastroenterology drugs, including IBD therapies. The company markets its products in more than 175 countries.
- Pfizer Inc.
Headquarters: New York, USA | Founded: 1849
Key Areas: JAK inhibitors, small molecule immunomodulators, inflammation
Pfizer is expanding its IBD offerings with tofacitinib (Xeljanz), a JAK inhibitor approved for ulcerative colitis. The company is also exploring filgotinib through a strategic partnership, solidifying its position in small-molecule therapies for gastrointestinal inflammation.
- Bristol Myers Squibb (BMS)
Headquarters: New York, USA | Founded: 1887
Key Areas: Immuno-oncology, protein degradation, autoimmune diseases
Bristol-Myers Squibb Co. is a global biopharmaceutical company focusing on cardiovascular, anti-infective, and anticancer therapies. The company undertakes the discovery, development, licensing, manufacture, marketing, and distribution of biopharmaceuticals and related healthcare products. It also focuses on psychiatric disorders, diabetes, hepatitis B, HIV/AIDS, and rheumatoid arthritis.
- Amgen Inc.
Headquarters: California, USA | Founded: 1980
Key Areas: General medicine, inflammation/autoimmune, oncology
Amgen offers biosimilars and biologics in the IBD space and is focusing on expanding global access to its therapies. The company is investing in next-gen biologics for Crohn’s and ulcerative colitis, with a strong interest in real-world data to support clinical outcomes.
- Ironwood Pharmaceuticals
Headquarters: Massachusetts, USA | Founded: 1998
Key Areas: Gastrointestinal (GI) health, rare GI diseases, GC-C agonists
Ironwood is a biopharmaceutical company focused on gastrointestinal disorders and rare diseases. It has strategic partnerships with many pharmaceutical companies, including AbbVie, AstraZeneca, and Astellas Pharma. Ironwood's strategy involves expanding its GI product pipeline and increasing the global supply of its commercialized products.
- Ardelyx Inc.
Headquarters: California, USA | Founded: 2007
Key Areas: GI & cardiorenal health, first-in-class NHE3 inhibitor, CKDrelated hyperphosphatemia
Ardelyx is focused on developing novel therapies for underserved gastrointestinal (GI) and kidney-related (cardiorenal) conditions using its proprietary NHE3 inhibitor, tenapanor. It currently markets two products in the U.S.: IBSRELA for IBSC and XPHOZAH for hyperphosphatemia in CKD on dialysis, all as tenapanor formulations.
- Celltrion
Headquarters: Incheon, South Korea | Founded: 2002
Key Areas: Global distribution of biosimilars; mAb biosimilar therapeutics for autoimmune diseases and oncology.
Celltrion Healthcare is the commercial and distribution arm of Celltrion, Inc., responsible for globally marketing and distributing biologics and biosimilars developed in Celltrion’s R&D and manufacturing network. Its products reach over 100 countries through direct and partner distribution channels across the Americas, Europe, Asia, CIS, and the Middle East, making it Korea’s leading exporter of biosimilars.
- UCB S.A.
Headquarters: Brussels, Belgium | Founded: 1928
Key Areas: Neurology (epilepsy, Parkinson’s, myasthenia gravis), immunology (TNF‑α, IL‑17 targets)
UCB is a global biopharmaceutical company focused on developing innovative therapies for people living with severe neurological and immunological diseases, particularly epilepsy, Parkinson’s disease, myasthenia gravis, and various autoimmune disorders.
Conclusion
The global IBS and IBD therapeutics market is transforming. As the need for personalized, effective, and accessible treatments continues to rise, these companies are leading the charge, blending science, strategy, and innovation.
With the market projected to reach $52.6 billion by 2030, IBS and IBD therapies are no longer niche specialties. They are central to global efforts to improve digestive health and chronic disease management.
